ATE517104T1 - Beta-carbolinderivate und deren pharmazeutische verwendung gegen depression und angst - Google Patents

Beta-carbolinderivate und deren pharmazeutische verwendung gegen depression und angst

Info

Publication number
ATE517104T1
ATE517104T1 AT02745204T AT02745204T ATE517104T1 AT E517104 T1 ATE517104 T1 AT E517104T1 AT 02745204 T AT02745204 T AT 02745204T AT 02745204 T AT02745204 T AT 02745204T AT E517104 T1 ATE517104 T1 AT E517104T1
Authority
AT
Austria
Prior art keywords
anxiety
beta
pharmaceutical use
use against
carboline derivatives
Prior art date
Application number
AT02745204T
Other languages
German (de)
English (en)
Inventor
Thomas Troxler
Konstanze Hurth
Daniel Hoyer
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE517104T1 publication Critical patent/ATE517104T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT02745204T 2001-04-03 2002-04-02 Beta-carbolinderivate und deren pharmazeutische verwendung gegen depression und angst ATE517104T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0108337.7A GB0108337D0 (en) 2001-04-03 2001-04-03 Organic compounds
PCT/EP2002/003624 WO2002081471A1 (en) 2001-04-03 2002-04-02 Beta-carboline derivatives and its pharmaceutical use against depression and anxiety

Publications (1)

Publication Number Publication Date
ATE517104T1 true ATE517104T1 (de) 2011-08-15

Family

ID=9912165

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02745204T ATE517104T1 (de) 2001-04-03 2002-04-02 Beta-carbolinderivate und deren pharmazeutische verwendung gegen depression und angst

Country Status (27)

Country Link
US (1) US6861430B2 (enExample)
EP (1) EP1377578B1 (enExample)
JP (1) JP4405732B2 (enExample)
KR (1) KR100564840B1 (enExample)
CN (1) CN1309721C (enExample)
AR (1) AR035451A1 (enExample)
AT (1) ATE517104T1 (enExample)
AU (1) AU2002316828B2 (enExample)
BR (1) BR0208566B1 (enExample)
CA (1) CA2440014C (enExample)
CZ (1) CZ295992B6 (enExample)
EC (1) ECSP034754A (enExample)
ES (1) ES2368389T3 (enExample)
GB (1) GB0108337D0 (enExample)
HU (1) HUP0400317A3 (enExample)
IL (1) IL157545A0 (enExample)
MX (1) MXPA03009057A (enExample)
MY (1) MY134026A (enExample)
NO (1) NO20034413D0 (enExample)
NZ (1) NZ528370A (enExample)
PE (1) PE20021018A1 (enExample)
PL (1) PL210861B1 (enExample)
PT (1) PT1377578E (enExample)
RU (1) RU2003130644A (enExample)
SK (1) SK12222003A3 (enExample)
WO (1) WO2002081471A1 (enExample)
ZA (1) ZA200306108B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
WO2004113300A1 (ja) * 2003-06-23 2004-12-29 Ono Pharmaceutical Co., Ltd. 新規三環性複素環化合物
AR051780A1 (es) * 2004-11-29 2007-02-07 Japan Tobacco Inc Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
EP1829874B1 (en) 2004-12-22 2014-02-12 Ono Pharmaceutical Co., Ltd. Tricyclic compound and use thereof
WO2007062175A2 (en) * 2005-11-21 2007-05-31 Amgen Inc. Spiro-substituted tricyclic heterocycles cxcr3 antagonists
US7879859B2 (en) * 2005-11-21 2011-02-01 Merck Sharp & Dohme Corp. Diagnosis and treatment of type 2 diabetes and other disorders
EP2178537A4 (en) * 2007-07-19 2011-08-17 Merck Sharp & Dohme BETA-CARBOLIN DERIVATIVES AS ANTIDIBLE COMPOUNDS
WO2009016329A1 (en) * 2007-07-31 2009-02-05 Cambridge Enterprise Limited Use of gabaa receptor antagonists to treat cognitive impairment in patients with psychiatric conditions
EP2300466B1 (en) 2008-06-20 2014-08-06 Bristol-Myers Squibb Company Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors
HUE026815T2 (en) 2008-11-19 2016-07-28 Forum Pharmaceuticals Inc Treatment of Cognitive Disorders with (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
TW201028414A (en) 2009-01-16 2010-08-01 Merck Sharp & Dohme Oxadiazole beta carboline derivatives as antidiabetic compounds
EP2523558A4 (en) 2010-01-15 2013-06-19 Merck Sharp & Dohme OXADIAZOL BETA CARBOLIN DERIVATIVES AS ANTIDIBLE COMPOUNDS
TWI519532B (zh) 2010-05-17 2016-02-01 艾維沃製藥公司 (R)-7-氯-N-(啶-3-基)苯並[b]噻吩-2-羧醯胺鹽酸鹽單水合物之結晶形體
RU2017136693A (ru) 2012-05-08 2019-02-08 Форум Фармасьютикалз, Инк. Способы поддержания, лечения или улучшения когнитивной функции
CN111349096B (zh) * 2020-04-14 2021-03-09 石河子大学 一种吲哚类化合物及其制备方法、应用
KR102467844B1 (ko) 2021-04-21 2022-11-16 삼성전자주식회사 솔리드 스테이트 드라이브 장치 및 이를 포함하는 데이터 저장 장치

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4118741A1 (de) * 1991-06-05 1992-12-10 Schering Ag Neue hetaryloxy-(beta)-carboline, deren herstellung und verwendung in arzneimitteln
US6057340A (en) * 1998-02-03 2000-05-02 American Home Products Corporation Oxazole derivatives as serotonin-1A receptor agonists
EP1086101B1 (en) 1998-06-12 2002-12-18 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Beta-carboline compounds

Also Published As

Publication number Publication date
PL362571A1 (en) 2004-11-02
NZ528370A (en) 2005-10-28
CZ20032655A3 (cs) 2003-12-17
BR0208566A (pt) 2004-03-30
NO20034413L (no) 2003-10-02
RU2003130644A (ru) 2005-04-10
ECSP034754A (es) 2003-10-28
WO2002081471A1 (en) 2002-10-17
PE20021018A1 (es) 2003-01-13
HUP0400317A3 (en) 2007-10-29
EP1377578A1 (en) 2004-01-07
ES2368389T3 (es) 2011-11-16
JP2004525178A (ja) 2004-08-19
JP4405732B2 (ja) 2010-01-27
ZA200306108B (en) 2004-07-05
IL157545A0 (en) 2004-03-28
US6861430B2 (en) 2005-03-01
US20040132735A1 (en) 2004-07-08
CN1309721C (zh) 2007-04-11
NO20034413D0 (no) 2003-10-02
GB0108337D0 (en) 2001-05-23
AR035451A1 (es) 2004-05-26
SK12222003A3 (sk) 2004-06-08
HUP0400317A2 (hu) 2004-09-28
EP1377578B1 (en) 2011-07-20
KR20040008150A (ko) 2004-01-28
KR100564840B1 (ko) 2006-03-28
AU2002316828B2 (en) 2006-05-11
CZ295992B6 (cs) 2005-12-14
CA2440014A1 (en) 2002-10-17
PT1377578E (pt) 2011-09-23
PL210861B1 (pl) 2012-03-30
CA2440014C (en) 2010-11-23
BR0208566B1 (pt) 2013-12-24
CN1500090A (zh) 2004-05-26
MXPA03009057A (es) 2004-02-12
MY134026A (en) 2007-11-30

Similar Documents

Publication Publication Date Title
DE60226704D1 (de) Acylierte 6,7,8,9-tetrahydro-5h-benzocycloheptenyl-amine und deren pharmazeutische verwendung
ATE370958T1 (de) Phosphonooxy-chinazolin derivate und ihre pharmazeutische verwendung
ATA13842001A (de) Chitosan-thio-alkyl-amidin konjugate und deren kosmetische sowie pharmazeutische verwendung
DE60208351D1 (de) Glukopyranosyloxybenzylbenzolderivate und deren medizinische verwendung
DE60230591D1 (de) Glykopyranosyloxypyrazolderivate und deren medizinische verwendung
DE60237580D1 (de) Glykopyranosyloxypyrazolderivate und deren medizinische verwendung
ATE551322T1 (de) 3-z-1-(4-(n-((4-methylpiperazin-1- yl)methylcarbonyl)-n-methylamino)anilino)1- phenylmethylen-6-methoxycarbonyl-2- indolinonmonoethansulfonat und dessen verwendung als pharmazeutische zusammensetzung
ATE472534T1 (de) Benzimidazolderivate: herstellung und pharmazeutische anwendungen
DE50212302D1 (de) 17alpha-alkyl-17beta-oxy-estratriene und zwischenprodukte zu deren herstellung, verwendung der 17alpha-alkyl-17beta-oxy-estratriene zur herstellung von arzneimitteln sowie pharmazeutische präparate
DE60201988D1 (de) Pharmazeutische dosierungsform von amorphem nilfenavir mesylat
ATE312613T1 (de) Niedrig dosierte entecavir formulierung und deren verwendung
CY2013032I2 (el) Συζυγη της εξενδινης-4 και η φαρμακευτικη τους χρηση
DE50312747D1 (de) Neue xanthinderivate, deren herstellung und deren verwendung als arzneimittel
DE50312295D1 (de) 8-ä3-amino-piperidin-1-ylü -xanthine, deren herstellung und deren verwendung als arzneimittel
ATE438639T1 (de) 2-cyanopyrrolidin-derivate und ihre verwendung als arzneimittel
ATE365717T1 (de) Acridin-derivate und deren verwendung als arzneimittel
DE60201859D1 (de) Pharmazeutische Verwendung von N-Carbamoylazol-Derivate
EE200200607A (et) 2-atsüülindoolderivaadid ja nende kasutamine kasvajavastaste ravimitena
DE60305037D1 (de) Piperazinylacylpiperidinderivate, deren herstellung und deren therapeutische anwendung
DE60037816D1 (de) Pharmazeutische formulierung enthaltend megalatran und dessen pro-pharmaka
DE50206476D1 (de) Cyanoanthranylamid-derivate und deren verwendung als arzneimittel
IL157545A0 (en) Beta-carboline derivatives and their pharmaceutical use against depression and anxiety
DE50113867D1 (de) Neue indolderivate und deren verwendung als arzneimittel
ATE491710T1 (de) 2-substituierte phenyl-5,7-dialkyl-3,7- dihydropyrrolä2,3-dü pyrimidin-4-onderivate, deren herstellung und pharmazeutische verwendung
DE60336999D1 (de) Melatonin enthaltende pharmazeutische formulierung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1377578

Country of ref document: EP